Generic drug makers are supposed to be the industry’s steady engine—lower prices, broader access, and predictable margins. But the reality is messier. According to DrugPatentWatch’s latest analysis, a growing list of forces is squeezing generic pharma …
8 Problems Killing Generic Pharma’s Margins (And How the Industry Is Fighting Back) Read Post »
Branded pharma’s revenue model is under siege—and the threats aren’t subtle.
In a recent piece, DrugPatentWatch lays out eight “brutal problems” that are quietly (and sometimes loudly) eroding the economics of branded drug companies. The headline takea…
8 Brutal Problems Killing Branded Pharma’s Revenue Model Read Post »
Generic drug competition isn’t won in the lab—it’s won in the filing. And nowhere is that more obvious than in the FDA’s Orange Book, where the “time and win” playbook for market entry is quietly written.
If you’ve ever wondered how generic manufacture…
The FDA Orange Book Decoded: How Generic Drug Makers Find, Time, and Win Market Entry Read Post »
Biopharma is hiring for “innovation,” but too many teams still build IP like it’s an afterthought.
Here’s the problem: when IP portfolios are treated as standalone assets—rather than as a living map of how a company actually organizes work—recruiting b…
The Generic Cliff Isn’t a Cliff—It’s a Deadline. Here’s How Pharma Engineers Around It.
If you’ve ever watched a blockbuster drug’s patent clock run down, you know the story: once exclusivity expires, generics rush in, prices fall, and revenue curves b…
Drug companies don’t just “get patents.” They build ecosystems.
That’s the uncomfortable truth behind how patent thickets form around biologic blockbusters—and why the fight over access, pricing, and innovation is increasingly a fight over patent str…
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after you’ve licensed, invested, hired counsel, and filed. But in pharma, the real cost often…
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay Read Post »
Most teams look at patents the wrong way.
They read claims like a verdict—either you’re “in” or you’re “out.” But formulation patents rarely work like that. In practice, they’re more like a map of constraints: what a competitor can’t do, what they mi…
Russia’s latest VED/SSM list update is a reminder that “generic timing” isn’t just a legal exercise—it’s an intelligence game.
If you’re a brand team, you’re watching for signals that competitors are lining up their launch calendars. If you’re a generi…
Russia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration Data Read Post »
Pharma pipelines don’t fail because of science. They fail because of freedom-to-operate.
That’s the uncomfortable truth many teams learn too late: a brilliant molecule can still get stuck—or worse, blocked—by patents, exclusivities, and licensing lan…
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline Read Post »
Get new actionable insights and updates from BiotechBlog
